Insulin resistance and insulin sensitizers

Hormone Research

Volumn 55, Issue SUPPL. 2, 2001, Pages 3-13

  Stumvoll, Michael ^a   Häring, Hans ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Genetic factors; Glucose disposal; Glucose intolerance; Insulin; Insulin resistance; Insulin sensitizers; Obesity; Type 2 diabetes mellitus

Indexed keywords

ALANINE; ARGININE; CALPAIN; FATTY ACID; GLUCOSE; GLYCINE; HORMONE; INSULIN; INSULIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROLINE; RESISTIN; ROSIGLITAZONE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ATHEROSCLEROSIS; CHROMOSOME 2; CONFERENCE PAPER; DYSLIPIDEMIA; GENETIC POLYMORPHISM; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEREDITY; HUMAN; HYPERTENSION; IMMOBILIZATION; INDIAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOLYSIS; MOLECULAR CLONING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SIGNAL TRANSDUCTION; THROMBOCYTE DYSFUNCTION;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; THIAZOLES;

EID: 0035743452     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000063466     Document Type: Conference Paper

References (106)

1. Pathogenesis of non-insulin-dependent diabetes mellitus
2. Cellular insulin action and insulin resistance
3. Insulin resistance - Mechanisms, syndromes, and implications
4. Glucose clamp technique: A method for quantifying insulin secretion and resistance
5. Multiple sites of insulin resistance: Muscle, liver and adipose tissue
6. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus
7. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance
8. Obesity and insulin resistance in humans: A dose-response study
9. Insulin dose-response characteristics for suppression of glycerol release and conversion to glucose in humans
10. Regulation of free fatty acid metabolism by insulin in humans: Role of lipolysis and reesterification
11. Fat metabolism in human obesity
12. Effect of insulin on oxidative and nonoxidative pathways of free fatty acid metabolism in human obesity
13. Suppression of systemic, intramuscular and subcutaneous adipose tissue lipolysis by insulin in humans
14. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus
15. Pathophysiology and pharmacological treatment of insulin resistance
16. Hyperglycemia and cardiovascular disease in type 2 diabetes
17. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease
18. Role of insulin resistance in human disease
19. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone
20. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM
21. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance
22. Insulin resistance and the effect of insulin on blood pressure in essential hypertension
23. Insulin resistance and macrovascular disease
24. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance
25. Hyperlipidaemia in diabetes
26. Insulin, insulin resistance and platelet function: Similarities with insulin effects on cultured vascular smooth muscle cells
27. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM
28. Glucose and free fatty acid metabolism in human obesity
29. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus
30. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus
31. Rapid impairment of skeletal muscle glucose transport/phosphorylation by free fatty acids in humans
32. Mechanism of free fatty acid-induced insulin resistance in humans
33. Glucose fatty acid interactions and the regulation of glucose disposal
34. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus
35. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
36. Role of non-esterified fatty acids in the pathogenesis of type 2 diabetes
37. Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadricep muscle and adipose tissue. Evidence for significant lipolysis in skeletal muscle
38. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects
39. Lipolysis in muscle is rapidly regulated by low physiologic doses of insulin
40. The role of TNF-alpha in human adipose tissue: Prevention of weight gain at the expense of insulin resistance?
41. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance
42. The interaction between obesity and diabetes
43. Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling
44. The hormone resistin links obesity to diabetes
45. Insulin action and age. European Group for the Study of Insulin Resistance (EGIR)
46. Role of insulin resistance in the pathogenesis of NIDDM
47. Exercise and the metabolic syndrome
48. Insulin action and insulin resistance in human skeletal muscle
49. Exercise, glucose transport, and insulin sensitivity
50. The insulin signalling system and the IRS proteins
51. Insulin receptors and insulin action
52. Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from NIDDM subjects
53. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects
54. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation
55. Role of human skeletal muscle insulin receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes mellitus and obesity
56. Impaired autophosphorylation of insulin receptors from abdominal skeletal muscles in nonobese subjects with NIDDM
57. Insulin-sensitive tyrosine kinase: Relationship with in vivo insulin action in humans
58. Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 (non-insulin-dependent) diabetes mellitus
59. A defective intramolecular autoactivation cascade may cause the reduced kinase activity of the skeletal muscle insulin receptor from patients with non-insulin-dependent diabetes mellitus
60. Concordance rate for type II diabetes mellitus in monozygotic twins: Actuarial analysis
61. Insulin sensitivity and insulin secretion in monozygotic and dizygotic twins
62. NIDDM associated with mutation in tyrosine kinase domain of insulin receptor gene
63. Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT-4) in patients with common-type non-insulin-dependent diabetes mellitus
64. Detection of mutations in insulin-receptor gene in NIDDM patients by analysis of single-stranded conformation polymorphisms
65. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies
66. The Gly-Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells
67. Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus
68. Variant sequences of insulin receptor substrate-1 in patients with noninsulin-dependent diabetes mellitus
69. UKPDS 19: Heterogeneity in NIDDM: Separate contributions of IRS-1 and beta 3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations. UK prospective diabetes study
70. Insulin receptor substrate (IRS-1) gene polymorphisms in French NIDDM families
71. Insulin resistance: Interactions between obesity and a common variant of insulin receptor substrate-1
72. The common PPAR gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
73. Amino acid polymorphism Gly 972 Arg in IRS-1 is not associated to lower clamp-derived insulin sensitivity in young healthy first degree relatives of patients with type 2 diabetes
74. The Gly972Arg polymorphism in the insulin receptor substrate-1 gene contributes to the variation in insulin secretion in normal glucose-tolerant humans
75. The Gly972→Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells
76. The common Arg972 polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets
77. Disruption of IRS-2 causes type 2 diabetes in mice
78. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance
79. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes
80. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2
81. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus
82. A calapin-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance
83. Calpain 10: The first positional cloning of a gene for type 2 diabetes
84. PPAR-gamma, the ultimate thrifty gene
85. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor
86. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations
87. Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women
88. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 gene is associated with increased antilipolytic insulin sensitivity
89. The PPARgamma2 polymorphism Pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients
90. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
91. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency
92. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
93. A novel use of the hyperinsulinemic-euglycemic clamp technique to estimate insulin sensitivity of systemic lipolysis
94. Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation
95. Suppression of hepatic gluconeogenesis in long-term troglitazone-treated diabetic KK and C57BL/KsJ-db/db mice
96. Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice
97. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexyl-methoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent
98. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
99. Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells
100. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor
101. Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes
102. Troglitazone action is independent of adipose tissue
103. Peroxisome proliferator-activated receptors, orphans with ligands and functions
104. Altered gene expression for tumor necrosis factor-α and its receptor during drug and dietary modulation of insulin resistance
105. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma
106. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes